Why the Starpharma (ASX:SPL) share price raced higher today

The biopharmaceutical company's shares are continuing their positive run this week…

| More on:
a group of doctors and medical staff in uniform high five in celebration in a hospital setting

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price finished in the green today following a positive release by the company.

At Tuesday's market close, the biopharmaceutical company's shares were up 3.46% to $1.345.

What did Starpharma announce?

Starpharma announced the results for its multiple dose clinical safety study for its Viraleze antiviral nasal spray.

The company said the product was very well tolerated, with no notable or serious adverse events reported.

Starpharma also confirmed the antiviral agent in Viraleze, SPL7013, was not absorbed into the bloodstream following repeated nasal application. This is in line with previous non-clinical and clinical data.

The randomised, double-blind study involved 40 healthy volunteers who used Viraleze four times a day for a 2-week period. The primary objective of the trial was to assess the safety and tolerability of Viraleze.

Starpharma CEO Dr Jackie Fairley commented:

We are pleased to report that Viraleze was very well tolerated in the study. This additional clinical data adds to the extensive body of evidence for SPL7013, demonstrating its extremely benign safety profile and confirming lack of systemic absorption of SPL7013 in Viraleze. These data further support the suitability of Viraleze antiviral nasal spray for use in everyday situations as a preventative product where individuals may be at risk of exposure to respiratory viruses.

An antiviral nasal spray like Viraleze is advantageous because respiratory viruses, including SARS-CoV-2, take hold by initially infecting mucosal cells in the nasal cavity, and Viraleze and SPL7013 form a barrier that traps and irreversibly inactivates viruses before they can infect cells.

Quick take on Viraleze

Viraleze is an antiviral nasal spray that has shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses. This includes multiple variants of SARS-CoV-2 (COVID-19), influenza, RSV, SARS, and MERS (Middle East Respiratory Syndrome).

Starpharma's Viraleze is currently registered for sale in Europe and India. It is not approved for sale or supply in Australia.

About the Starpharma share price

Over the last 12 months, Starpharma shares gained 27%, but tracked the other way in 2021, down 13%.

Starpharma presides a market capitalisation of roughly $548.2 million, with approximately 406 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a bountiful session for investors this hump day.

Read more »

An excited man stretches his arms out above his head as he reaches a mountain peak.
Record Highs

Breaking: CBA shares hit a new record of $180

CBA shares can't possibly keep rising can they?

Read more »

A happy young couple celebrate a win by jumping high above their new sofa.
52-Week Highs

Guess which ASX 200 furniture retailer is up 400% in 5 years?

Up 400% over the past five years is not bad for a furniture retailer. Here's why this quiet compounder has…

Read more »

Arrows pointing upwards with a man pointing his finger at one.
Share Market News

Morgans says these ASX stocks can rise 30% to 80%

These shares could be cheap according to the broker. Let's see what it is saying.

Read more »

Two people shaking hands in the boardroom on a merger.
Mergers & Acquisitions

What did Macquarie make of the Brickworks and Soul Patts merger?

Macquarie sees simplification, scale, and upside… but it also has a warning..

Read more »

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
Mergers & Acquisitions

PointsBet share price surges 11% on improved takeover offer

The bidding war for PointsBet shares continues apace today.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Leading broker tips 50%+ upside for IDP Education shares

The team at Macquarie thinks this beaten down stock could be a buy.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »